More than halfway through the US Food and Drug Administration’s guidance development effort on patient-focused drug development, the agency is receiving plaudits for its work, but industry and patient advocates continue to voice some key concerns that could become topics for discussion in the next round of user fee negotiations.
In 2019, the agency released the second of four draft guidance documents required under the 21st Century Cures Act and...








